A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS.
about
Clinical practice. Irritable bowel syndromeIrritable bowel syndromeNew and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologistsDiagnosis and treatment of diarrhea-predominant irritable bowel syndromeThe clinical potential of ramosetron in the treatment of irritable bowel syndrome with diarrhea (IBS-D)Review article: the treatment of functional abdominal bloating and distension.Pharmacologic and complementary and alternative medicine therapies for irritable bowel syndrome.Ramosetron in irritable bowel syndrome with diarrhea: new hope or the same old story?An Evidence-Based Look at Misconceptions in the Treatment of Patients with IBS-DMeta-analysis: do irritable bowel syndrome symptoms vary between men and women?Irritable bowel syndrome: a review article.Lubiprostone: evaluation of the newest medication for the treatment of adult women with constipation-predominant irritable bowel syndromeTargeted therapies for diarrhea-predominant irritable bowel syndrome.Pharmacogenomics and functional gastrointestinal disorders.Efficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trialsTreatment of Dientamoeba fragilis in patients with irritable bowel syndrome.Emerging drugs for irritable bowel syndrome.Review article: modulation of the brain-gut axis as a therapeutic approach in gastrointestinal disease.Is there an experimental basis for the development of ischaemic colitis as a result of 5-HT3 antagonist treatment?Mechanisms of hypersensitivity in IBS and functional disorders.Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials.Long-term efficacy and safety of ramosetron in the treatment of diarrhea-predominant irritable bowel syndrome.New treatments for irritable bowel syndrome in womenNeural and psychological predictors of treatment response in irritable bowel syndrome patients with a 5-HT3 receptor antagonist: a pilot studyThe HTR3A polymorphism c. -42C>T is associated with amygdala responsiveness in patients with irritable bowel syndrome.Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles.Cilansetron in the treatment of diarrhea-predominant irritable bowel syndrome?Therapeutic advances in functional gastrointestinal disease: irritable bowel syndrome.Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis.Alosetron: an effective treatment for diarrhea-predominant irritable bowel syndrome.Randomized, placebo-controlled, phase IV pilot study of ramosetron to evaluate the co-primary end points in male patients with irritable bowel syndrome with diarrhea.New treatments for IBS.Current and future pharmacological treatments for diarrhea-predominant irritable bowel syndrome.Evaluating the functional net value of pharmacologic agents in treating irritable bowel syndrome.American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation.Current and emerging pharmacotherapeutic options for irritable bowel syndrome.Current and emerging drug options in the treatment of diarrhea predominant irritable bowel syndrome.Recommendations for pharmacological clinical trials in children with irritable bowel syndrome: the Rome foundation pediatric subcommittee on clinical trials.Randomised clinical trial: the clinical effects of a novel neurokinin receptor antagonist, DNK333, in women with diarrhoea-predominant irritable bowel syndrome.Sex-Related Differences in GI Disorders.
P2860
Q24602718-0305A7E3-08CE-434D-8CA6-5E67BDE3C3B8Q24670113-49C6FCFB-DF80-4B20-8BA5-7BC423484CC8Q26748617-F9D0F0AF-AB52-46B9-A488-2AEE49BB08A8Q26765272-CA7C7607-A07E-4351-AFBF-A821319B8B80Q27024521-D315A621-F933-4B1C-B812-670497F0F39CQ33450132-785BEA13-9C4E-47A6-AF8E-0FDDAB1E40B8Q33451900-27AB9853-C967-4CE9-8E30-BA8EDD3ECF69Q33656496-F4D89CDB-D364-4E18-8071-0985E052BA98Q33667183-6603B6BF-3848-43D6-98B0-08F8D451D8B0Q34101503-E3F28578-4692-4011-BA48-FF127B95838DQ34134491-E1E65B35-BD29-43DA-842A-0ED1A99DF48AQ34345704-EF18F15B-8A61-44FB-A5B3-7784A00BF04CQ36065945-70673150-30AC-4CD1-85EA-79A87A1F590CQ36192802-E83E721B-AA53-4054-A17C-14FA48244C70Q36307366-D745F101-211F-4390-A9C9-FCB41FA951DCQ36450117-2D949618-1EAB-488B-B42D-7AC051668FECQ36458417-5FD3A85A-5073-4B37-9511-3C2B08A82742Q36583822-536A9F90-1E15-4D11-B316-D98B29846BF3Q36715880-8B87DED4-720B-4281-BB97-39F75D92EDE4Q36728934-7A397B3E-55CD-433E-9B06-0AFDAE83439AQ36983944-6E1C8586-095A-4914-8D5F-D5AFAC8E93A3Q37057059-B7D2B24B-4EA9-491E-B44C-FD2AD40F9FFDQ37120300-21E6F737-9360-48ED-B280-744039CCE545Q37130193-D7AC9592-9F74-4CED-BBAB-F87015C444B5Q37134075-AB0788E3-D773-4E2A-83B9-5351CBF4B451Q37164063-87AE8AE6-E21D-47CC-9529-7D8395C0D2A2Q37346021-9CEFC6D1-2A11-4A1F-8B1E-DC6B8F210012Q37426287-18518176-FD4A-4677-B579-9B6AB0DFA806Q37496549-3F4E0CD5-3092-4139-A999-A4725559D4C1Q37608344-BF821013-0CF8-484E-8949-44609794C2D6Q37708383-E61AFA1F-DA14-4D16-A8EF-B32BA0B46D02Q38059436-AD7DCE8C-0255-45AE-9295-AF5828B23C45Q38102063-96C8287A-49EA-4DBB-AA19-759BB8E655EDQ38194631-EDCEC13B-1888-46D3-8FB4-579DA7666792Q38236812-E2CA74D0-D9ED-45DD-9C06-4FD08AB30555Q38254747-4F5CCE18-2B0A-4A70-9869-1A91C6DA5AEFQ38630721-3607D8E2-104B-4203-AB5A-0D174F510DAAQ38914226-337E1038-8775-401C-97C7-E637C94704DCQ39267149-A742A8A9-2415-4D47-8FB6-7DE94C7AAE0EQ39303889-58D717BE-0812-486D-B433-5228EBBF5109
P2860
A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
A dose-ranging, phase II study ...... with diarrhea-predominant IBS.
@en
A dose-ranging, phase II study ...... with diarrhea-predominant IBS.
@nl
type
label
A dose-ranging, phase II study ...... with diarrhea-predominant IBS.
@en
A dose-ranging, phase II study ...... with diarrhea-predominant IBS.
@nl
prefLabel
A dose-ranging, phase II study ...... with diarrhea-predominant IBS.
@en
A dose-ranging, phase II study ...... with diarrhea-predominant IBS.
@nl
P2093
P2860
P1476
A dose-ranging, phase II study ...... with diarrhea-predominant IBS.
@en
P2093
David J McSorley
Emeran A Mayer
Eric G Carter
George E Dukes
Vanessa Z Ameen
P2860
P304
P356
10.1111/J.1572-0241.2005.40365.X
P407
P577
2005-01-01T00:00:00Z